Previous Close | 22.00 |
Open | 22.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's Range | 22.00 - 22.00 |
52 Week Range | 20.15 - 29.80 |
Volume | |
Avg. Volume | 0 |
Market Cap | 3.791B |
Beta (5Y Monthly) | 0.55 |
PE Ratio (TTM) | 7.05 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024.
Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. NT1 is associated with an absence or significant deficiency